Glatiramer acetate

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Copaxone)
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Copaxone or glatopa, and glatiramer, its generic form, is glatiramer acetate (copaxone), an FDA-approved immunomodulator licensed to reduce relapses in patients with multiple sclerosis.[1]

ME/CFS[edit | edit source]

Dr. Ron Davis on Copaxone in ME/CFS. Inaugural Harvard Symposium, Sep 2019.

Ron Davis of the Open Medicine Foundation reports that when the nanoneedle electrical impedance test on ME/CFS cells was used, Copaxone made the cells respond in the same way as healthy cells did, suggesting it is a potential treatment for ME/CFS.[2]

Notable studies[edit | edit source]

  • 2023, Catalytic Antibodies May Contribute to Demyelination in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[3] - (Full text)

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]